Minimal residual disease assessment in multiple myeloma by multiparametric flow cytometry

Authors

RIHOVA L. VŠIANSKÁ Pavla BEZDĚKOVÁ Renata KRÁLOVÁ Romana PENKA Miroslav KREJČÍ Marta POUR Luděk HAJEK R.

Year of publication 2017
Type Article in Periodical
Magazine / Source Klinická onkologie
MU Faculty or unit

Faculty of Medicine

Citation
Doi http://dx.doi.org/10.14735/amko20172S21
Field Oncology and hematology
Keywords flow cytometry; minimal residual disease; multiple myeloma; plasma cells
Description Background: Progress in treatment of multiple myeloma extensively increased patient remission rates, so minimal residual disease (MRD) detection becomes essential to assess the effectivity of treatment and depth of complete response. Nowadays, multiparametric flow cytometry(MFC) is the most used method for monitoring of MRD presence in the bone marrow of multiple myeloma patients; however, detection on molecular level can be used as well. It is evident that choice of protocol used for MFC-MRD assessment can significantly affect required results;nevertheless, standardized and highly sensitive approach of "next generation flow" is already available. Although benefit of MRD assessment as an independent predictor of progression- -free survival and over all survival is known, very recent research showed that MRD-negative status surpasses the prognostic value of complete response achievement for progression-free survival and over all survival. Aim: This review is focused on use MFC in MRD assessment in multiple myeloma. The technical aspects and clinical benefits of this approach are mentioned as well. Conclusion: The information about MRD level detected by highly sensitive and reproducible MFC can be potentially used as a bio marker to evaluate the efficacy of different treatment strategies, help on treatment decisions and act as a surrogate for over all survival in multiple myeloma patients.

You are running an old browser version. We recommend updating your browser to its latest version.

More info